Follow the entities shaping the evidence.

…els are single patient cohorts (0.1 µg/kg starting MABEL dose). CT-95 is delivered as weekly IV infusions, with steroid premedication…

…plasmic immune checkpoint, constraining immune cell activation. NX-1607 is a first-in-class, orally bioavailable, small-molecule inhibi…

…d regulations of the University of Virginia and approved by the University of Virginia Animal Care and Use Committee.References Demir ZEF, Sheybani ND…

…t al. An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function. Leuk Res. 2018 Nov;74:68–7…

…r can suppress Treg cell-induced immunosuppression, sensitizing breast cancer cells to immunotherapy-driven anti-tumor responses. Hence, an a…

… only CAR T-cell therapy for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [Internet]. Bristol M…

…temic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS) are closely associated with B cell dysregulation. Recently…

… group has demonstrated that the histone deacetylase inhibitor, entinostat, decreases the immunosuppression by MDSCs, and when combined wi…

…able engagement by tumor cell-opsonizing antibodies. Therefore, F9H4 represents a new opportunity in cancer immunotherapy research.E…

…Background Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is the third lea…

…suggesting that DC inclusion dampens the macrophage response to bemcentinib.9 Separation of macrophages by A375 state was further reflected…

…fy proteins that synergize with IL-12 locally and systemically. IL-12 IVEP was also combined with intratumoral delivery of cowpea mos…